NASDAQ: VAXX - Vaxxinity, Inc.

Rentabilität für sechs Monate: -87.4%
Sektor: Healthcare

Aktionsplan Vaxxinity, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.

Weitere Details
The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Выручка 0.000557
EBITDA -0.0136
P/BV 5.47
P/S 10658.34
EV/EBITDA -1.02
Цена ао 0.65
ISIN US92244V1044
Число акций ао 0.12651 млрд
Сайт https://www.vaxxinity.com
Валюта usd
IPO date 2021-11-11
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Preisänderung pro Tag: +1 400% (0.004)
Preisänderung pro Woche: +2 900% (0.002)
Preisänderung pro Monat: +20% (0.05)
Preisänderung über 3 Monate: -70% (0.2)
Preisänderung über sechs Monate: -87.4% (0.4761)
Preisänderung pro Jahr: -93.87% (0.978)
Preisänderung seit Jahresbeginn: -94.23% (1.04)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 9.72 1
P/E 0 0
EV/EBITDA -2.51 0
Gesamt: 2.63

Effizienz

Name Bedeutung Grad
ROA, % -128.37 0
ROE, % -424.6 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.2706 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -100.18 0
Rentabilität Ebitda, % -99.59 0
Rentabilität EPS, % 294.77 10
Gesamt: 4
Weitere Details

Institutionen Volumen Aktie, %
Prime Movers Lab, LLC 15744167 13.95
Adage Capital Partners GP L.L.C. 3000000 2.66
Blackrock Inc. 2526951 2.24
Vanguard Group Inc 2377385 2.11
State Street Corporation 832473 0.74
Geode Capital Management, LLC 829802 0.74
Bank of America Corporation 499557 0.44
Northern Trust Corporation 351812 0.31
Creative Planning 278646 0.25
Pathstone Family Office, LLC 153846 0.14



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Louis Garfield Reese IV Co-Founder & Executive Chairman of the Board 83.28k 1982 (42 Jahr)
Ms. Mei Mei Hu J.D. Co-Founder, President, CEO & Director 551.73k 1983 (41 Jahr)
Mr. Jason Pesile CPA, M.B.A. Chief Accounting Officer N/A 1973 (51 Jahr)
Ms. Sumita Ray J.D. Chief Legal, Compliance & Administrative Officer and Corporate Secretary N/A 1974 (50 Jahre)
Mr. Mark Joinnides MSE Chief of Staff N/A
Dr. Jean-Cosme Dodart Ph.D. Chief Scientific Officer N/A
Dr. Manal Morsy M.B.A., M.D., PH.D. Chief Regulatory Officer

Adresse: United States, Merritt Island. FL, 505 Odyssey Way - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.vaxxinity.com